RxDoctor Payments Data

Patrick Cronin, DO

Rheumatology · Voorhees, NJNPI 1194817486

Payments from drug & device makers

$1,987in general payments, 2019–2025

Across 136 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$804
  • Novartis$275
  • Johnson & Johnson$258
  • Amgen$171
  • AstraZeneca$119
  • E.r. Squibb & Sons, L.L.C.$80
  • plus $280 from 7 others

What the payments were for

  • Food & beverage$1,86994%
  • Education$1196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,987 in reported general payments places this provider in the 45th percentile of 234 rheumatology providers in New Jersey.

See all rheumatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$687,968
Medicare patients
404
Services billed
31,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab79$723,244
RinvoqUpadacitinib87$657,978
Xeljanz XrTofacitinib Citrate39$289,389
Enbrel SureclickEtanercept32$259,347
Cimzia (2 Pack)Certolizumab Pegol26$152,558
Orencia ClickjectAbatacept16$140,459
BenlystaBelimumab38$137,505
Teriparatide38$126,662
Simponi AriaGolimumab14$106,712
ProliaDenosumab55$98,340
Humira PenAdalimumab13$92,906
RemicadeInfliximab13$92,407
ForteoTeriparatide18$91,734
OtezlaApremilast18$88,490
OrenciaAbatacept/Maltose19$86,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$804$657,97887 claims
Johnson & JohnsonSimponi Aria, Remicade$258$199,11927 claims
AmgenProlia, Otezla$171$186,82973 claims
UCB, Inc.Cimzia (2 Pack)$62$152,55826 claims
GSKBenlysta$27$137,50538 claims
E.r. Squibb & Sons, L.L.C.Orencia$80$86,83419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 234 rheumatology providers in New Jersey.

Other rheumatology in Voorhees

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →